Active Filter(s):
Details:
Under this agreement, Delpharm will manufacture AzurRx’s MS1819 cGMP batch that will be used in the Phase 2b OPTION 2 Clinical Trial for the treatment of EPI in patients with Cystic Fibrosis.
Lead Product(s): MS1819
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: First Wave BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 16, 2020